A tumor DNA complex aberration index is an independent predictor of survival in breast and ovarian cancer

[1]  Carlos Caldas,et al.  The implications of clonal genome evolution for cancer medicine. , 2013, The New England journal of medicine.

[2]  A. Børresen-Dale,et al.  Copynumber: Efficient algorithms for single- and multi-track copy number segmentation , 2012, BMC Genomics.

[3]  S. Tavaré,et al.  Calling Sample Mix-Ups in Cancer Population Studies , 2012, PloS one.

[4]  S. Cross,et al.  PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2 , 2012, British Journal of Cancer.

[5]  F. Markowetz,et al.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.

[6]  Christopher McCabe,et al.  Economic evaluation of genomic test-directed chemotherapy for early-stage lymph node-positive breast cancer. , 2012, Journal of the National Cancer Institute.

[7]  Z. Yakhini,et al.  Ischemia caused by time to freezing induces systematic microRNA and mRNA responses in cancer tissue , 2011, Molecular oncology.

[8]  E. Rutgers,et al.  The EORTC 10041/BIG 03-04 MINDACT trial is feasible: results of the pilot phase. , 2011, European journal of cancer.

[9]  X. Chen,et al.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. , 2011, The Journal of clinical investigation.

[10]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[11]  Ewout W. Steyerberg,et al.  Focus on : Contemporary Methods in Biostatistics ( I ) Regression Modeling Strategies , 2017 .

[12]  C. Caldas,et al.  A population-based validation of the prognostic model PREDICT for early breast cancer. , 2011, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[13]  Ewout W Steyerberg,et al.  Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers , 2011, Statistics in medicine.

[14]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[15]  A. Krasnitz,et al.  Genomic Architecture Characterizes Tumor Progression Paths and Fate in Breast Cancer Patients , 2010, Science Translational Medicine.

[16]  Päivi Heikkilä,et al.  Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies , 2010, PLoS medicine.

[17]  Derek Y. Chiang,et al.  The landscape of somatic copy-number alteration across human cancers , 2010, Nature.

[18]  Carlos Caldas,et al.  PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer , 2010, Breast Cancer Research.

[19]  Terence P. Speed,et al.  A single-array preprocessing method for estimating full-resolution raw copy numbers from all Affymetrix genotyping arrays including GenomeWideSNP 5 & 6 , 2009, Bioinform..

[20]  R. Gelber,et al.  Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009 , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  Joshy George,et al.  Integrated Genome-Wide DNA Copy Number and Expression Analysis Identifies Distinct Mechanisms of Primary Chemoresistance in Ovarian Carcinomas , 2009, Clinical Cancer Research.

[22]  L. V. van't Veer,et al.  Clinical application of the 70-gene profile: the MINDACT trial. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  S. Paik,et al.  Development of the 21-gene assay and its application in clinical practice and clinical trials. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  M. Pencina,et al.  Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond , 2008, Statistics in medicine.

[25]  Fatima Cardoso,et al.  The MINDACT trial: The first prospective clinical validation of a genomic tool , 2007, Molecular oncology.

[26]  R. Ozols,et al.  Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Kenny Q. Ye,et al.  Novel patterns of genome rearrangement and their association with survival in breast cancer. , 2006, Genome research.

[28]  J. Sparano,et al.  TAILORx: trial assigning individualized options for treatment (Rx). , 2006, Clinical breast cancer.

[29]  D G Altman,et al.  REporting recommendations for tumour MARKer prognostic studies (REMARK) , 2005, British journal of cancer.

[30]  Douglas G Altman,et al.  REporting recommendations for tumour MARKer prognostic studies (REMARK). , 2005, European journal of cancer.

[31]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[32]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[33]  Jean YH Yang,et al.  Bioconductor: open software development for computational biology and bioinformatics , 2004, Genome Biology.

[34]  Brigitte M. Ronnett,et al.  The Histologic Type and Stage Distribution of Ovarian Carcinomas of Surface Epithelial Origin , 2004, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[35]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[36]  P. Kantoff,et al.  Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  Van,et al.  A gene-expression signature as a predictor of survival in breast cancer. , 2002, The New England journal of medicine.

[38]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[39]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[40]  P. Ravdin,et al.  Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  Frank E. Harrell,et al.  Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis , 2001 .

[42]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[43]  Ozols Rf.  Update of the NCCN ovarian cancer practice guidelines , 1997 .

[44]  F. Harrell,et al.  Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .

[45]  D. Grimes,et al.  Relative frequency of primary ovarian neoplasms: A 10‐year review , 1989, Obstetrics and gynecology.

[46]  S. Rubin,et al.  Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  R. Ozols.  Update of the NCCN ovarian cancer practice guidelines. , 1997, Oncology.

[48]  J. Berek,et al.  Ovarian Cancer 3 , 1994, Springer US.

[49]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.